South Korea
· Delayed Price · Currency is KRW Union Korea Pharm Statistics
Total Valuation
Union Korea Pharm has a market cap or net worth of KRW 19.70 billion. The enterprise value is 51.10 billion.
| Market Cap | 19.70B |
| Enterprise Value | 51.10B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Union Korea Pharm has 7.23 million shares outstanding. The number of shares has decreased by -0.29% in one year.
| Shares Outstanding | 7.23M |
| Shares Change (YoY) | -0.29% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 11.20% |
| Owned by Institutions (%) | n/a |
| Float | 6.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.31 |
| PB Ratio | 0.84 |
| P/FCF Ratio | 3.78 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.24 |
| EV / Sales | 0.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 9.81 |
Financial Position
The company has a current ratio of 0.77, with a Debt / Equity ratio of 1.66.
| Current Ratio | 0.77 |
| Quick Ratio | 0.57 |
| Debt / Equity | 1.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | 7.49 |
| Interest Coverage | -3.98 |
Financial Efficiency
Return on equity (ROE) is -65.16% and return on invested capital (ROIC) is -14.49%.
| Return on Equity (ROE) | -65.16% |
| Return on Assets (ROA) | -10.49% |
| Return on Capital (ROIC) | -14.49% |
| Revenue Per Employee | 326.00M |
| Profits Per Employee | -115.62M |
| Employee Count | 197 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 3.52 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -43.76% |
| 50-Day Moving Average | 4,377.90 |
| 200-Day Moving Average | 5,128.30 |
| Relative Strength Index (RSI) | 32.14 |
| Average Volume (20 Days) | 426,612 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Union Korea Pharm had revenue of KRW 64.22 billion and -22.78 billion in losses. Loss per share was -3,154.77.
| Revenue | 64.22B |
| Gross Profit | 23.31B |
| Operating Income | -16.96B |
| Pretax Income | -19.03B |
| Net Income | -22.78B |
| EBITDA | -13.37B |
| EBIT | -16.96B |
| Loss Per Share | -3,154.77 |
Balance Sheet
The company has 7.58 billion in cash and 38.98 billion in debt, giving a net cash position of -31.40 billion or -4,343.07 per share.
| Cash & Cash Equivalents | 7.58B |
| Total Debt | 38.98B |
| Net Cash | -31.40B |
| Net Cash Per Share | -4,343.07 |
| Equity (Book Value) | 23.51B |
| Book Value Per Share | 3,251.99 |
| Working Capital | -14.48B |
Cash Flow
In the last 12 months, operating cash flow was 6.68 billion and capital expenditures -1.48 billion, giving a free cash flow of 5.21 billion.
| Operating Cash Flow | 6.68B |
| Capital Expenditures | -1.48B |
| Free Cash Flow | 5.21B |
| FCF Per Share | 720.15 |
Margins
Gross margin is 36.29%, with operating and profit margins of -26.41% and -35.47%.
| Gross Margin | 36.29% |
| Operating Margin | -26.41% |
| Pretax Margin | -29.63% |
| Profit Margin | -35.47% |
| EBITDA Margin | -20.82% |
| EBIT Margin | -26.41% |
| FCF Margin | 8.11% |
Dividends & Yields
Union Korea Pharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.29% |
| Shareholder Yield | 0.29% |
| Earnings Yield | -115.77% |
| FCF Yield | 26.43% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Union Korea Pharm has an Altman Z-Score of -0.08. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.08 |
| Piotroski F-Score | n/a |